VW
MRNA icon

Vantage Wealth’s Moderna MRNA Stock Holding History

Vantage Wealth’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,460
Closed -$245K – 38
2023
Q4 		$245K Sell
2,460
-2,255
-48% -$190K 0.05% 36
2023
Q3 		$487K Sell
4,715
-1,375
-23% -$153K 0.12% 32
2023
Q2 		$740K Sell
6,090
-50
-0.8% -$6.67K 0.19% 26
2023
Q1 		$943K Hold
6,140
– – 0.26% 25
2022
Q4 		$1.1M Sell
6,140
-400
-6% -$65.4K 0.28% 25
2022
Q3 		$773K Sell
6,540
-25
-0.4% -$3.79K 0.21% 26
2022
Q2 		$938K Hold
6,565
– – 0.26% 24
2022
Q1 		$1.13M Buy
6,565
+125
+2% +$21K 0.25% 25
2021
Q4 		$1.64M Hold
6,440
– – 0.36% 25
2021
Q3 		$2.48M Sell
6,440
-1,800
-22% -$664K 0.63% 25
2021
Q2 		$1.94M Buy
8,240
+375
+5% +$67K 0.47% 26
2021
Q1 		$1.03M Buy
+7,865
New +$1.14M 0.26% 27

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vantage Wealth's MRNA Position: Q1 2024 in Review

Vantage Wealth sold out of Moderna (MRNA) in Q1 2024, closing a stake of 2,460 shares — an estimated $245K sold.

Vantage Wealth first reported a position in MRNA in Q1 2021 and held it in 12 quarters. The position peaked at $2.48M in Q3 2021. 903 funds tracked by Wall St. Rank hold MRNA as of Q1 2024.

  • Vantage Wealth reported no remaining Moderna position as of Q1 2024 after selling out during the quarter.
  • Vantage Wealth sold 2,460 Moderna shares in Q1 2024, an estimated $245K.
  • Vantage Wealth first reported a position in Moderna in Q1 2021 and held it in 12 quarters.
  • Vantage Wealth's Moderna position peaked at $2.48M in Q3 2021.
  • 903 funds tracked by Wall St. Rank held Moderna as of Q1 2024.

Based on Vantage Wealth's 13F filing for Q1 2024, filed 9 Apr 2024.